Company news

Share this article:
Pfizer has received antitrust approval in its bid to purchase Encysive Pharmaceuticals for about $195 million. The company's offer to buy outstanding Encysive shares for $2.35 apiece expires at the end of March 31. The deal was announced last month.
Pfizer is looking to purchase Encysive to bolster is high blood pressure product portfolio.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions